Get the Stockscreener App
8.355
3.40%
0.275
Genelux Corp stock is traded at $8.355, with a volume of 150.14K.
It is up +3.40% in the last 24 hours and up +87.75% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
See More
Previous Close:
$8.08
Open:
$8.12
24h Volume:
150.14K
Relative Volume:
0.94
Market Cap:
$314.65M
Revenue:
-
Net Income/Loss:
$-27.66M
P/E Ratio:
-8.7947
EPS:
-0.95
Net Cash Flow:
$-24.36M
1W Performance:
+14.45%
1M Performance:
+87.75%
6M Performance:
+217.68%
1Y Performance:
+160.28%
1-Day Range:
$7.764
$8.461
1-Week Range:
$7.25
$8.461
52-Week Range:
$1.9875
$8.461
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
8.33 | 305.21M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.62 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.93 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.49 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.27 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.13 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Lake Street | Buy |
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
View All
Genelux Corp Stock (GNLX) Latest News
Statistical indicators supporting Genelux Corporation’s strengthTrade Risk Summary & Short-Term High Return Ideas - newser.com
Volume spikes in Genelux Corporation stock – what they meanBond Market & Weekly High Potential Stock Alerts - newser.com
What MACD and RSI say about Genelux Corporation2025 Geopolitical Influence & AI Driven Price Predictions - newser.com
Combining machine learning predictions for Genelux CorporationInflation Watch & Smart Money Movement Alerts - newser.com
Genelux (NASDAQ:GNLX) Trading Up 3.4%Still a Buy? - MarketBeat
Is Genelux Corporation stock trading near support levelsJuly 2025 Selloffs & Real-Time Volume Analysis - newser.com
Genelux initiated with a Buy at Titan Partners - TipRanks
Will earnings trigger a reversal in Genelux CorporationSwing Trade & Reliable Volume Spike Alerts - newser.com
Will Genelux Corporation stock keep outperforming rivalsTrend Reversal & Free Reliable Trade Execution Plans - newser.com
How buybacks impact Genelux Corporation stock value2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
What MACD signals say about Genelux CorporationJuly 2025 Weekly Recap & High Accuracy Investment Signals - newser.com
Visual trend scoring systems applied to Genelux Corporation2025 Geopolitical Influence & AI Driven Price Predictions - newser.com
Intraday pattern recognizer results for Genelux Corporation2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Will Genelux Corporation see short term momentum2025 Historical Comparison & Stepwise Swing Trade Plans - newser.com
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment - TipRanks
Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment - TipRanks
Multi factor analysis applied to Genelux CorporationTrade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
Genelux Corporation stock volume spike explainedPortfolio Growth Summary & Free Risk Controlled Daily Trade Plans - newser.com
Genelux (NASDAQ:GNLX) Earns Sell (E+) Rating from Weiss Ratings - MarketBeat
Analysts Set Genelux Corporation (NASDAQ:GNLX) Price Target at $19.25 - Defense World
Genelux Corporation stock retracement – recovery analysis2025 Major Catalysts & High Accuracy Trade Alerts - newser.com
Genelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum - TipRanks
GNLX: Lake Street Initiates Coverage with 'Buy' Rating and $16 P - GuruFocus
Lake Street Capital Markets initiates Genelux stock with Buy rating By Investing.com - Investing.com Philippines
Lake Street Capital Markets initiates Genelux stock with Buy rating - Investing.com India
Genelux initiated with a Buy at Lake Street - TipRanks
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):